Travere Therapeutics (TVTX) EBT Margin (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly EBT Margin came in at 28.87% in Q1 2026, up 2152.0% YoY from 1.28% in Q1 2025, and down 582.06% on a QoQ basis from 5.99% in Q4 2025.
Travere Therapeutics (TVTX) EBT Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of EBT Margin data on file, last reported at 28.87% in Q1 2026.
- Quarterly EBT Margin rose 2152.0% year-over-year to 28.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.93% (up 14653.0% YoY) and the FY2025 annual result came in at 529.82%, down 39236.0% from the prior year.
- EBT Margin eased to 28.87% in Q1 2026, from 5.99% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 64.28% in Q3 2025 to a low of 348.94% in Q1 2022.
- A 5-year average of 172.31% and a median of 196.47% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin sank 34777 bps — and 2025, when it soared 27775 bps.
- Tracing TVTX's EBT Margin over 5 years: stood at 291.67% in 2022, then surged by 33 bps to 196.47% in 2023, then soared by 59 bps to 80.68% in 2024, then surged by 107 bps to 5.99% in 2025, then tumbled by 582 bps to 28.87% in 2026.
- The last three EBT Margin figures came in at 28.87% (Q1 2026), 5.99% (Q4 2025), and 64.28% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -20.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.64% |
| Mar 31, 2026 | -28.87% |
| Dec 31, 2025 | 5.99% |
| Sep 30, 2025 | 64.29% |
| Jun 30, 2025 | -11.13% |
| Mar 31, 2025 | -50.39% |
| Dec 31, 2024 | -80.68% |
| Sep 30, 2024 | -87.18% |
| Jun 30, 2024 | -128.55% |
| Mar 31, 2024 | -328.15% |
| Dec 31, 2023 | -196.47% |
| Sep 30, 2023 | -240.54% |
| Jun 30, 2023 | -316.40% |
| Mar 31, 2023 | -312.37% |
| Dec 31, 2022 | -291.67% |
| Sep 30, 2022 | -298.91% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -348.94% |
| Dec 31, 2021 | 56.10% |
| Sep 30, 2021 | -52.18% |